The EnFix implant was awarded the coveted ACE
Award for "Accelerating the Cutting Edge" during the annual meeting
of the American Orthopaedic Society for Sports Medicine
(AOSSM)
LOS
ANGELES, July 17, 2024 /PRNewswire/
-- TETROUS, INC., a Sherman
Oaks start up focused on bone-to-tendon healing following
orthopedic surgery, announced today that it was the sole recipient
of this year's ACE Award for "Accelerating the Cutting Edge" at the
recent AOSSM annual conference held in Denver, CO. Although this honor is
typically given to 2 or 3 innovative technologies in the industry,
this year the committee stated the EnFix technology is a true "game
changer" and presented Tetrous as the sole recipient.
...we selected Tetrous as this year's sole
award winner. Their technology is truly innovative and a real
game changer.
"We are truly grateful for this award from AOSSM" stated
Andy Carter, PhD, co-founder and CTO
of Tetrous. He continued, "We have worked diligently in
creating a technology that directly addresses the current high rate
of failure in rotator cuff surgeries and other orthopedic
procedures by remodeling the enthesis, the region where the tendon
attaches to the bone. It is very rewarding that the industry
is recognizing this unique technology."
More than 500 EnFix RC™ and EnFix TAC™ have been implanted in a
controlled release in the US and Australia over the past 12 months.
Follow up MRIs on patients at six months post-surgery are
consistently showing reformation of the enthesis, thickening of the
tendon and little to no edema. While the majority of the
procedures have been for rotator cuff, there are additional
applications for this technology in hip, achilles and ACL
procedures.
"We reviewed applications from a wide variety of companies for
the 2024 ACE award," stated Dr. Brian
Busconi, orthopaedic surgeon and ACE award committee
member. "After careful consideration and individual meetings
with the finalists, we selected Tetrous as this year's sole award
winner. Their technology is truly innovative and a real game
changer."
Tetrous is actively expanding its distribution team in the US
and adding new surgeons that have requested the EnFix implants for
their rotator cuff surgeries. The Tetrous team will be
attending the Shoulder and Elbow Society Association (SESA) meeting
in Brisbane in October to further
expand its business in Australia.
About Tetrous, Inc.
Founded in 2019, Tetrous, Inc.
utilizes next generation advanced technologies for enthesis repair
in sports medicine applications. The first offerings in the EnFix
family of products are EnFix RC and EnFix TAC for rotator cuff
repair. Tetrous was conceived from technology developed for spine
surgery. The Company is employing and expanding the technology for
novel applications in sports medicine. Its core technology has been
used in over 100,000 implants in spine applications. The
demineralized bone fiber technology used in Tetrous products is
licensed exclusively for use in sports medicine from TheraCell, an
ISTO Biologics Company. EnFix®, EnFix RC™ and EnFix TAC™ are
trademarks of Tetrous, Inc.
For more information visit www.tetrous.com and follow us
on LinkedIn (www.linkedin.com/company/tetrous).
Media
Contact:
|
Product
Information:
|
Bradley Patt, PhD
|
John
Bojanowski
|
Tetrous, Inc.
|
Tetrous,
Inc.
|
331-307-7499
|
331-307-7499
|
bpatt@tetrous.com
|
jbojanowski@tetrous.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tetrous-wins-major-award-at-top-sports-medicine-conference-for-its-enfix-implant-302199229.html
SOURCE Tetrous